TuesdayJan 05, 2021 12:11 pm

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FRA: 0C0) to Benefit as Countries Seek Natural Options for Crops Protection

Demand for food increasing as world population swells; pesticides paramount to maintain supply Countries banning pesticides deemed hazardous, but alternatives are lacking MustGrow is solution provider for global food supply with its natural biological crop protection for high-value crops As the world population is increasing at an accelerated pace, a stable food supply is becoming critical to ensure food availability across the world. MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is playing a key role in providing biotechnology that secures both steady and high-quality crop supply. To ensure a consistent flow of produce, crops need protection. For that, producers have…

Continue Reading

TuesdayJan 05, 2021 11:30 am

Study Finds Genes May Not Be Main Cause of Childhood Obesity

Obesity during childhood is a challenge for many children. However, there may be hope, as German researchers have discovered that social, environmental and behavioral factors influence weight loss significantly, while obesity genes play a minor role in successful weight loss. The recent study carried out by the Technical University of Munich (TUM) suggests that there are vital things to consider with regard to treatment strategies for obesity in children. Melanie Heitkamp, a researcher from TUM’s department of prevention, sports medicine and rehabilitation, explained that using an individual’s genetic predisposition as a basis for their likelihood to respond to a treatment…

Continue Reading

MondayJan 04, 2021 2:08 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Conducts Public Offering Funding Effort, Appears in Syndicated Broadcast on Brain Cancer Drug Advances

Neuro-oncology drug developer CNS Pharmaceuticals is completing an underwritten public offering of common stock shares and warrants in a bid to fund its upcoming Phase 2 trials for a candidate in fighting glioblastoma brain cancers CNS’s Phase 2 trials are scheduled to begin during Q1 of 2021, building on a Phase 1 trial in which 44 percent of patients saw improvement and one patient has survived cancer-free for nearly 15 years The company has designed an ambitious, adaptive trial that allows for an interim analysis of data and adjustments for efficiency in bringing the drug candidate, Berubicin, to hoped-for approval…

Continue Reading

MondayJan 04, 2021 12:43 pm

Brain Scientific Inc. (BRSF) Offers Solutions to Flatten COVID-19 Curve

Over one-third of hospitalized individuals are in danger of suffering neurological issues Traditional EEGs present various challenges, including cross-contamination NeuroCap(TM) makes EEGs more accessible, sanitary Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company with two FDA-cleared products, provides next-gen solutions to the neurology market. Neurological care that reduces the opportunity of cross-contamination is critically needed in the effort to combat COVID-19. According to the CDC's national forecast data, the United States is predicted to report a new record of COVID-19 cases, anticipated to number between 1 million and 2.3 million new cases the week ending Jan. 2, 2021 (https://ibn.fm/NveF2). A recent…

Continue Reading

MondayJan 04, 2021 12:15 pm

Genetics May Help Prevent Decline in Cognitive Function

While some individuals suffer from dementia or Alzheimer’s as they get older, others tend to remain sharp well past the age of 80. German researchers have found the reason for this: an individual’s genes. The researchers’ conclusion is based on findings from a study that involved studying the brain images of 94 participants who were 80 years old and above. The images were made up of the amount of beta-amyloid protein plaques and tau protein tangles discovered in the participants’ brains. Researchers found that individuals who had lower scores on memory tests were those who were aging normally. These participants…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050